ArticleCommunications medicine2025
Impact of androgen receptor pathway inhibitors on cognitive function in older adults treated for metastatic prostate cancer.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02907372 (Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundAndrogen receptor pathway inhibitors (ARPI) are commonly used in addition to androgen deprivation therapy (ADT) for metastatic prostate cancer (mPC). Despite preliminary results suggesting effects of ADT+ARPI on cognition, there is limited data on their impact in older adults. The objective was to assess cognition in mPC patients ≥70 years receiving ADT+ARPI.
methodsThis observational study (COG-PRO trial, NCT02907372, registered on 26/07/2016) recruited castration-resistant mPC patients (aged ≥70) receiving ADT+ARPI, patients receiving ADT alone, and healthy controls (HC). Cognition was prospectively assessed using a self-report questionnaire (subjective cognition) and cognitive tests addressing six domains: processing speed/attention, working memory, verbal memory, visual memory, visuospatial abilities, and executive functions (objective cognition). Rates of patients with impairment before ARPI initiation and decline after 3, 6 and 12 months were estimated using international recommendations. Adjusted scores were then analyzed with linear models.
resultsWe report that at baseline (before starting ARPI for ADT+ARPI patients), objective cognitive impairment affects 36 (51%), 5 (26%) and 3 (10%) ADT+ARPI patients, ADT patients and HC, respectively. After 3 and 6 months of follow-up, adjusted scores show poorer subjective cognition in ADT+ARPI patients than in ADT patients (p ≤ 0.033). ADT+ARPI patients also have lower objective performance in processing speed/attention domain at all visits (p ≤ 0.010).
conclusionsAlthough limited by small sample sizes, our study shows that ARPI + ADT can increase the risk of impacting objective and subjective cognition in older adults with mPC, compared to ADT alone. Clinician should use specific measures of objective and subjective cognition to assess ARPI-induced cognitive changes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.